A Phase III Trial of Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastasis
Sheng Lu(Shanghai Jiao Tong University), Zhenggang Zhu(Wuhan Center for Disease Control and Prevention), Chao Yan(Shanghai Jiao Tong University), Xuexin Yao(Shanghai Jiao Tong University), Yanan Zheng(Zhejiang Chinese Medical University), Birendra Kumar Sah(Ruijin Hospital), Runhua Feng(Shanghai Jiao Tong University), Min Yan(Zhengzhou University), Mingmin Chen(Medizinische Hochschule Hannover), Chen Li(Shanghai Jiao Tong University), Wentao Liu(Institute of Metal Research), Changyu He(Shanghai Jiao Tong University), Zichen Hua(Shanghai Jiao Tong University), Zhentian Ni(Ruijin Hospital), Zhongyin Yang(Shanghai Jiao Tong University), Zhenqiang Wang(Shanghai Jiao Tong University), Zhenglun Zhu(Brigham and Women's Hospital)
Cited by 16
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
|Oncotarget|2017|400
miR-126 functions as a tumour suppressor in human gastric cancer
|Cancer Letters|2010|298
CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway
|Journal of Experimental & Clinical Cancer Research|2019|231
Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell
|World Journal of Gastroenterology|2018|212